Affinia Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 51

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $40M

  • Investors
  • 19

Affinia Therapeutics General Information

Description

Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.

Contact Information

Formerly Known As
TDTx, TouchDownTx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 43 Foundry Avenue
  • Suite 120
  • Waltham, MA 02453
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Corporate Office
  • 43 Foundry Avenue
  • Suite 120
  • Waltham, MA 02453
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affinia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 07-Oct-2025 $40M Completed Generating Revenue
3. IPO 02-Dec-2022 Cancelled Generating Revenue
2. Early Stage VC (Series B) 03-May-2021 $110M $170M Completed Generating Revenue
1. Early Stage VC (Series A) 12-Mar-2020 $60M $60M Completed Generating Revenue
To view Affinia Therapeutics’s complete valuation and funding history, request access »

Affinia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A-1 23,736,223 $0.000100 $2.3 $2.3 1x $7.7 7.93%
Series A 3,706,187 $0.000100 $2.56 $2.56 1x $8.55 1.24%
To view Affinia Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Affinia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous
Drug Discovery
Waltham, MA
51 As of 2025

London, United Kingdom
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Affinia Therapeutics Competitors (5)

One of Affinia Therapeutics’s 5 competitors is Orchard Therapeutics, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orchard Therapeutics Formerly VC-backed London, United Kingdom
Autobahn Therapeutics Venture Capital-Backed San Diego, CA
Voyager Therapeutics Formerly VC-backed Lexington, MA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 5 competitors. Get the full list »

Affinia Therapeutics Patents

Affinia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236093-A1 Methods and compositions for treatment of bag3 mutation-associated dilated cardiomyopathy Pending 05-May-2025
WO-2026224683-A1 Recombinant aavs with improved tropism and specificity Pending 25-Apr-2025
WO-2025235491-A1 Recombinant aav for treatment of cardiac diseases Pending 07-May-2024
WO-2025227063-A1 Recombinant aavs with improved tropism and specificity Pending 26-Apr-2024
AU-2025235317-A1 Plasmid system for production of recombinant adenoassociated virus Pending 14-Mar-2024 C12N15/86
To view Affinia Therapeutics’s complete patent history, request access »

Affinia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affinia Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lilly USA Corporation Minority
Avidity Partners Asset Manager Minority
Casdin Capital Venture Capital Minority
EcoR1 Capital Venture Capital Minority
Eight Roads Corporate Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Affinia Therapeutics FAQs

  • When was Affinia Therapeutics founded?

    Affinia Therapeutics was founded in 2019.

  • Where is Affinia Therapeutics headquartered?

    Affinia Therapeutics is headquartered in Waltham, MA.

  • What is the size of Affinia Therapeutics?

    Affinia Therapeutics has 51 total employees.

  • What industry is Affinia Therapeutics in?

    Affinia Therapeutics’s primary industry is Drug Discovery.

  • Is Affinia Therapeutics a private or public company?

    Affinia Therapeutics is a Private company.

  • What is the current valuation of Affinia Therapeutics?

    The current valuation of Affinia Therapeutics is .

  • What is Affinia Therapeutics’s current revenue?

    The current revenue for Affinia Therapeutics is .

  • How much funding has Affinia Therapeutics raised over time?

    Affinia Therapeutics has raised $210M.

  • Who are Affinia Therapeutics’s investors?

    Lilly USA, Avidity Partners, Casdin Capital, EcoR1 Capital, and Eight Roads are 5 of 19 investors who have invested in Affinia Therapeutics.

  • Who are Affinia Therapeutics’s competitors?

    Orchard Therapeutics, Autobahn Therapeutics, Voyager Therapeutics, Genetix Biotherapeutics, and ACADIA Pharmaceuticals are competitors of Affinia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process